Share This Article:

The Role of Prolactin in the Evolution of Prostate Cancer

Full-Text HTML Download Download as PDF (Size:1378KB) PP. 188-197
DOI: 10.4236/oju.2012.223034    4,512 Downloads   7,482 Views   Citations


Today there is significant information indicating an effect of prolactin on the prostate gland. It has been shown to be involved in mechanisms leading to the synthesis of some proteins such as PSA and cathepsin D, synthesis of citrate and accumulation of zinc. Also, at the behavioral level, prolactin is known to control some aspects of reproduction, including documentation on the physiology of the prostate and the possibility to trigger pathologies in this sex gland. Although the later still is not clear, there is a correlation between the level of prolactin and the presence of prostate pathologies. Thus, the aim of this review is to show how prolactin is involved in the progression of some pathologies of this male sexual gland.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Elena Hernandez and M. J. Wilson, "The Role of Prolactin in the Evolution of Prostate Cancer," Open Journal of Urology, Vol. 2 No. 3A, 2012, pp. 188-197. doi: 10.4236/oju.2012.223034.


[1] A. Bachelot and N. Binart, “Reproductive Role of Prolactin,” Reproduction, Vol. 133, No. 2, 2007, pp. 361-369.
[2] N. Ben-Jonathan, C. R. LaPensee and E. W. LaPensee, “What Can We Learn From Rodents About Prolactin in Humans?” Endocrine Review, Vol. 29, No. 1, 2008, pp. 1-41.
[3] J. Neil and G. Nagy, “Prolactin Secretion and Its Control,” In: E. Knobil and J. D. Neill, Eds., The Physiology of Reproduction, Raven Press, New York, 1994, pp. 1833-1860.
[4] M. T. Nevalainen, E. M. Valve, P. M. Ingleton, M. Nurmi, P. M. Martikainen and P. L. Harkonen, “Prolactin and Prolactin Receptors Are Expressed in Human Prostate,” The Journal of Clinical Investigation, Vol. 99, No. 4, 1997, pp. 618-627.
[5] C. Boyle-Feysot, V. Goffin, M. Edery, N. Binart and P. Kelly, “Prolactin and Its Receptors: Actions, Signal Transduction pathways and phenotypes observed in PRL receptor knockout mice,” Endocrine Review, Vol. 19, No. 3, 1998, pp. 225-2268.
[6] J. Kindblom, K. Dillner, L. Sahlin, F. Robertson, C. Or- mandy, J. T?rnell and H. Wennbo “Prostate Hyperplasia in a Transgenic Mouse with Prostate-Specific Expresion of Prolactin,” Endocrinology, Vol. 144, No. 6, 2003, pp. 2269-2278.
[7] C. Nicoll, “Physiological Actions of Prolactin,” In: J. Field, H. Magoun and V. Hall, Eds., Handbook of Physiology. A Critical, Comprehensive Presentation of Physiological Knowledge and Concepts, American Physiological Society, 1994, pp. 263-264.
[8] T. J. Ahonen, P. L. Harkonen, H. Rui and M. T. Nevalainen, “PRL Signal Transduction in the Epithelial Compartment of Rat Prostate Maintained as Long-Term Organ Cultures in Vitro,” Endocrinology, Vol. 143, No. 1, 2002, pp. 228-238.
[9] F. Van Coppenolle, C. Slomianny, F. Carpentier, B. Le, A. Ahidouch, D. Croix, G. Legrand, F. Dewailly, S. Fornier, H. Caouss, D. Authie, J. Raynaud, C. Beauvillain, P. Dupouy and N. Prevarskaya, “Effects of Hyperprolactinemia on Rat Prostate Growth: Evidence of Androgen-Dependence,” American Journal of Physiology Endocrinology and Metabolism, Vol. 280, No. 1, 2001, pp. E120-129.
[10] L. C. Costello, Y. Liu, J. Zou and R. B. Franklin, “Evidence for a Zinc Uptake Transporter in Human Préstate Cancer Cells Which Is Regulated by Prolactin and Testosterone,” Journal of Biological Chemestry, Vol. 274, No. 25, 1999, p. 504.
[11] L. C. Costello and R. B. Franklin, “Effect of Prolactin on the Prostate,” Prostate, Vol. 24, No. 3, 1994, pp. 162-166.
[12] L. C. Costello, L. Lao and R. Franklin, “Citrate Modulation of High-Affinity Aspartate Transport in Prostate Epithelial Cells,” Cellular and Molecular Biology, Vol. 39, No. 5, 1993, pp. 515-524.
[13] E. Reiter, B. Hennuy, M. Bruyninx, A. Cornet, M. Klung, M. McNamara, J. Closset and G. Hennen, “Effects of Pituitary Hormones on the Prostate,” Prostate, Vol. 38, No. 2, 1999, pp. 159-165.
[14] J. Kindblom, “Actions of Prolactin in the Prostate Gland,” In: D. Hoseman, Ed., Prolactin, Kluwer Academic Publishers Inc., New York, 2001, pp. 233-245.
[15] G. S. Prins and C. Lee, “Biphasic Response of the Rat Lateral Prostate to Increasing Level of Serum Prolactin,” Biology of Reproduction, Vol. 29, No. 4, 1983, pp. 938-945.
[16] R. Diaz, “Niveles de Catepsina D Prostática en Respuesta a la Estimulación Sexual en Ratas” Ph.D. Thesis, Universidad Veracruzana, Veracruz, 2006.
[17] M. E. Hernández, A. Soto-Cid, G. E. Aranda-Abreu, R. Díaz, F. Rojas, L. I. Garcia, R. Toledo and J. Manzo, “A Study of the Prostate, Androgens and Sexual Activity of Ale Rats,” Reproductive Biology and Endocrinology, Vol. 16, No. 5, 2007, pp. 11-19.
[18] M. Silva, “Niveles de mRNA del Receptor a Prolactina en la Próstata Durante la Conducta Sexual de la Rata,” Ph.D. Thesis, Universidad Veracruzana, Veracruz, 2009.
[19] A. Soto-Cid, C. R. Hernandez-Kelly, M. E. Hernandez, J. Manzo, E. González-Mejia, R. C. Zepeda and A. Ortega, “Signal Transducers and Activators of Transcription 1 and 3 in Prostate: Effect of Sexual Activity,” Life Sciences, Vol. 79, No. 9, 2006, pp. 919-924.
[20] N. Binart, N. Melaine, C. Pineau, H. Kercret, A. M. Touzalin, P. Imbert-Bolloré, P. A. Kelly and B. Jégou, “Male Reproductive Function Is Not Affected in Prolactin Receptor-Deficient Mice,” Endocrinology, Vol. 144, No. 9, 2003, pp. 3779-3782.
[21] S. Odoma, G. D. Chisholm, K. Nicol and F. K. Habib, “Evidence for the Association between Blood Prolactin and Androgen Receptors in BPH,” Journal of Urology, Vol. 133, No. 4, 1985, pp. 717-720.
[22] J. Meng, C. H. Tsai-Morris and M. L. Dufau, “Human Prolactin Receptor Variants in Breast Cancer: Low Ratio of Short Forms to the Long-Form Human Prolactin Receptor Associated with Mammary Carcinoma,” Cancer Research, Vol. 64, No. 16, 2004, pp. 5677-5682.
[23] S. K. Peirce and W. Y. Chen, “Quantification of Prolactin Receptor mRNA in Multiple Human Tissues and Cancer Cell Lines by Real Time RT-PCR,” Journal of Endocrinology, Vol. 171, No. 1, 2001, pp. R1-R4.
[24] P. Lissoni, M. Mandala, F. Ropvelli, M. Casu, F. Rocco, G. Tancini and E. Scardino, “Paradoxical Stimulation of Prolactin Secretion by L-Dopa in Metastatico Prostate Cancer and Its Possible Role in Prostate-Cancer-Related Hyperprolactinemia,” European Urology, Vol. 37, No. 5, 2000, pp. 569-572.
[25] A. Negro-Vilar, W. A. Saad and S. M. McCann, “Evidence for a Role of Prolactin in Prostate and Seminal Vesicle Growth in Immature Male Rats,” Endocrinology, Vol. 100, No. 3, 1977, pp. 729-737.
[26] P. W. Harvey, D. J. Everett and C. J. Springall, “Adverse Effects of Prolactin in Rodents and Humans: Breast and Prostate Cancer,” Journal of Psichopharmacology, Vol. 22, No. 2, 2008, pp. 20-27.
[27] Y. de Launoit, R. Kiss, V. Jossa, M. Coibion, R. J. Paridaens, E. De Backer, A. J. Danguy and J. L. Pasteels, “Influences of Dihydrotestosterone, Testosterone, Estradiol, Progesterne, or Prolactin on the Cell Kinetics of Human Hyperprolastic Prostatic Tissue in Organ Culture,” Prostate, Vol. 13, No. 2, 1988, pp. 143-153.
[28] L. Romero, C. Mu?oz, A. López and J. Vilches, “Relation of Prolactin with Nodular Hyperplasia and Carcinoma of the Prostate,” Actas Urologicas Espa?olas, Vol. 15, No. 6, 1991, pp. 503-509.
[29] D. Giuffrida, A. Perdichizzi, M. C. Giuffrida, S. La Vignera, R. D’Agata, E. Vicari and A. E. Calogero, “Does Prolactin Induce Apoptosis? Evidences in a Prostate Cancer in Vitro Model,” Journal of Endocrinological Investigation, Vol. 33, No. 5, 2010, pp. 313-317.
[30] T. J. Ahonen, P. L. Harkonen, J. Laine, H. Rui, P. M. Martikainen and M. T. Nevalainen, “Prolactin Is a Survival Factor for Androgen-Deprived Rat Dorsal and Préstate Epithelium in Organ Culture,” Endocrinology, Vol. 140, No. 11, 1999, pp. 5412-5421.
[31] K. Dillner, J. Kindblom, A. Flores-Morales, R. Shao, J. T?rnell, G. Norstedt and H. Wennbo, “Gene Expression Analysis of Prostate Hyperplasia in Mice Overexpressing the Prolactin Gene Specifically in the Prostate,” Endocrinology, Vol. 144, No. 11, 2003, pp. 4955-4966.
[32] A. Colao, G. Vitale, A. Di Sarno, S. Spiezia, E. Guerra, A. Ciccarelli and A. Lombardi, “Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma,” Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 6, 2004, pp. 2770-2775.
[33] S. J. McPherson, H. Wang, M. E. Jones, J. Pedersen, T. P. Lismaa, N. Wreford, E. R. Simpson and G. P. Risbridger, “Elevated Androgens and Prolactin in Aromatesa-Defiicient Mice Cause Enlargement, but Not Malignancy, of the Prostate Gland,” Endocrinology, Vol. 142, No. 6, 2001, pp. 2458-2467.
[34] A. Ruffion, K. A. Al-Sakkaf, B. L. Brown, C. L. Eaton, F. C. Hamdy and P. R. Dobson, “The Survival Effect of Prolactin on PC3 Prostate Cancer Cells,” European Urology, Vol. 43, No. 3, 2003, pp. 301-308. doi:10.1016/S0302-2838(03)00038-1
[35] N. N. Tam, C. Y. Szeto, J. M. Freudenberg, A. N. Fullenkamp, M. Medvedovic and S. M. Ho, “Research Resource: Estrogen-Driven Prolactin-Mediated Gene-Expression Networks in Hormone-Induced Prostatic Intra- epithelial Neoplasia,” Molecular Endocrinology, Vol. 24, No. 11, 2010, pp. 2207-2217.
[36] Z. Z. Hu, “Study of the Interrelationship of Prolactin Secretion, Thyroid and Ovarian Function,” Zhonghua Fu Chan Ke Za Zhi, Vol. 19, No. 4, 1984, pp. 210-214.
[37] A. Ouhtit, G. Morel G and P. A. Kelly, “Visualization of Gene Expression of Short and Long Forms of Prolactin Receptor in Rat Reproductive Tissues,” Biology of Reproduction, Vol. 49, No. 3, 1993, pp. 528-536.
[38] J. Rillema, “Prolactin Actions. Encyclopedia of Reproduction,” Academic Press, New York, 1999.
[39] M. E. Freeman, B. Kanyicska, A. Lerant and G. Nagy, “Prolactin: Structure, Function, and Regulation of Secretion,” Physiological Review, Vol. 80, No. 4, 2000, pp. 1523-1631.
[40] J. Harris, P. M. Stanford, S. R. Oakes and C. J. Ormandy, “Prolactin and the Prolactin Receptor: New Targets of an Old Hormone,” Annals of Medicine, Vol. 36, No. 6, 2004, pp. 414-425.
[41] P. A. Kelly, N. Binart, M. Freemark, B. Lucas, V. Goffin and B. Bouchard, “Prolactin Receptor Signal Transduction Pathways and Actions Determined in Prolactin Receptor Knockout Mice,” Biochemical Society Transactions, Vol. 29, No. 2, 2001, pp. 48-52.
[42] I. Leav, F. B. Merk, K. F. Lee, M. Loda, M. Mandoki, J. E. McNeal and S. Ho, “Prolactin Receptor Expression in the Developing Human Prostate and in Hyperplastic, Dysplastic, and Neoplastic Lesions,” American Journal of Pathology, Vol. 154, No. 3, 1999, pp. 863-870.
[43] B. Lewis, “Traducción de Se?ales,” Oxford University Press, Oxford, 2001.
[44] G. Pearson, J. M. English, M. A. White and M. H. Cobb, “ERK5 and ERK2 Cooperate to Regulate NF-kappaB and Cell Transformation,” Journal of Biological Chemistry, Vol. 276, No. 11, 2001, pp. 7927-7931.
[45] G. Pearson, F. Robinson, G. T. Beers, B. E. Xu, M. Karandikar, K. Berman and M. H. Cobb, “Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions,” Endocrine Reviews, Vol. 22, No. 2, 2001b, pp. 153-183.
[46] R. Lefloch, J. Pouyssegur and P. Lenormand, “Single and Combined Silencing of ERK1 and ERK2 Reveals Their Positive Contribution to Growth Signaling Depending on Their Expression Levels,” Molecular Cell Biology, Vol. 28, No. 1, 2008, pp. 511-527.
[47] P. D. Maroni, S. Koul, R. B. Meacham and H. K. Koul, “Mitogen Activated Protein Kinase Signal Transduction Pathways in the Prostate,” Cell Communication and Signaling, Vol. 2, No. 1, 2004, pp. 114-123.
[48] M. A. Dominguez-Caceres, J. M. Garcia-Martinez, A. Calcabrini, L. Gonzalez, P. G. Porque, J. Leon and J. Martin-Perez, “Prolactin Induces c-Myc Expression and Cell Survival through Activation of Src/Akt Pathway in Lymphoid Cells,” Oncogene, Vol. 23, No. 44, 2004, pp. 7378-7390.
[49] J. Aguilera, “Comunicación Intra e Intercellular,” In: M. E. Hernández and A. Ortega, Eds., Fisiología Celular y Molecular: Principios y Conceptos, Universidad Veracruzana, Veracruz, 2004, pp. 97-112.
[50] K. L. Schwertfeger, S. Hunter, L. E. Heasley, V. Levresse, R. P. Leon, J. DeGregori and S. M. Anderson, “Prolactin Stimulates Activation of c-jun N-Terminal Kinase (JNK),” Molecular Endocrinology, Vol. 14, No. 10, 2000, pp. 1592-1602.
[51] A. Rufion, E. Fontaine and F. Staerman, “Hormonal Therapy in Metastatic Cancer,” Progress in Urology, Vol. 13, No. 2, 2003, pp. 334-341.
[52] L. Tangbanluekal and C. L. Robinette, “Prolactin Mediates Estradiol-Induced Inflammation in the Lateral Prostate of Wistar Rats,” Endocrinology, Vol. 132, No. 6, 1993, pp. 2407-2416.
[53] K. Berinder, O. Akre, F, Granath and A. L. Hulting, “Cancer Risk in Hyperprolactinemia Patines: A Population-Based Cohort Study,” European Journal of Endocrinology, Vol. 165, No. 2, 2011, pp. 209-215.
[54] J. F. Sissom, M. L. Eigenbrodt and J. C. Porter, “Anti-Growth Action on Mause Mammary and Prostate Glands of Monoclonal Antibody to Prolactin Receptor,” American Journal of Pathology, Vol. 133, No. 3, 1988, pp. 589-595.
[55] M. Ben-David, T. Kadar and A. V. Schally, “Micromethod for the Determination of Free and Total Prolactin Receptors: Measurement of Receptor Levels in Normal and Malignant Mammary and Prostate Tissues,” Proceedings of the National Academy of Sciences, Vol. 83, No. 21, 1986, pp. 8375-8379.
[56] J. R. Dave and R. J. Witorsch, “Prolactin Increases Lipid Fluidity and Prolactin Binding of Rat Prostatic Membranes,” American Journal of Physiology, Vol. 248, No. 6, 1985, pp. E687-E693.
[57] P. Mathey, “Efecto de la Hyperprolactinemia Sobre los Niveles de Expresión del RNA Mensajero Para el Receptor a Prolactina y vías de Se?alización en la Próstata,” Ph.D. Thesis, Universidad Veracruzana, México, 2011.
[58] W. Lou, Z. Ni, K. Dyer, D. J. Tweardy and A. C. Gao, “Interleukin-6 Induces Prostate Cancer Cell Growth Accompanied by Activation of State Signaling Pathway,” Prostate, Vol. 42, No. 3, 2000, pp. 239-242.
[59] M. T. Spiotto and T. D. Chung, “STAT3 Mediates IL-6-Induced Growth Inhibitionin the Human Prostate Cancer Cell Line LNCaP,” Prostate, Vol. 42, No. 2, 2000, pp. 88-98.
[60] L. Tam, L. M. McGlynn, P. Traynor, R. Mukherjee, J. M. S. Bartlett and J. Edwards, “Expression Levels of the JAK/STAT Pathway in the Transition from Hormone-Sensitive to Hormone-Refractory Prostate Cancer,” British Journal of Cancer, Vol. 97, No. 7, 2007, pp. 378-383.
[61] J. Abdulghani, L. Gu, A. Dagvadorj, J. Lutz, B. Leiby, G. Bonuccelli, M. P. Lisanti, T. Zellweger, K. Alanen, T. Mirtti, T. Visakorpi, L. Bubendorf and M. T. Nevalainen, “Stat3 Promotes Metastatic Progression of Prostate Cancer,” American Journal of Pathology, Vol. 172, No. 6, 2008, pp. 1717-1728. doi:10.2353/ajpath.2008.071054
[62] X. Liu, Z. He, C. H. Li, G. Huang, C. Ding and H. Liu, “Correlation Analysis of JAK-STAT Pathway Components on Prognosis of Patients with Prostate Cancer,” Pathology Oncology Research, Vol. 18, No. 1, 2012, pp. 17-23.
[63] A. Dagvadorj, S. H. Tan, Z. Liao, J. Xie, M. Nurmi, K. Alanen, H. Rui, T. Mirtti and M. T. Nevalainen, “N-Terminal Truncation of Stat5a/b Circumvents PIAS3- Mediated Transcriptional Inhibition of Stat5 in Prostate Cancer Cells,” International Journal of Biochemistry and Cell Biology, Vol. 42, No. 12, 2010, pp. 2037-2046.
[64] J. Lin, R. M. Adam, E. Santiestevan and M. R. Freeman, “The Phosphatidylinositol 30-Kinase Pathway Is a Dominant Growth Factor-Activated Cell Survival Pathway in LNCaP Human Prostate Carcinoma Cells,” Cancer Research, Vol. 59, No. 12, 1999, pp. 2891-2897.
[65] M. E. Cox, P. D. Deeble, S. Lakhani and S. J. Parsons, “Adquisition of Neuroendocrine Characteristics by Prostate Tumor Cells Is Reversible: Implicatios for Prostate Cancer Progression,” Cancer Research, Vol. 59, No. 15, 1999, pp. 3821-3830.
[66] M. E. Hernandez, A. Soto-Cid, F. Rojas, L. I. Pascual, G. E. Aranda-Abreu, R. Toledo, L. I. Garcia, A. Quintanar-Stephano and J. Manzo, “Prostate Response to Prolactin in Sexually Active Male Rats,” Reproductive Biology and Endocrinology, Vol. 14, No. 4, 2006, pp. 28-38.
[67] K. E. Lane, I. Leav, J. Ziar, R. S. Bridges, W. M. Rand and S. M. Ho, “Suppression of Testosterone and Estradiol-17beta-Induced Dysplasia in the Dorsolateral Prostate of Noble Rats by Bromocriptine,” Carcinogenesis, Vol. 18, No. 8, 1997, pp. 1505-1510.
[68] M. J. Linja, K. P. Porkka, Z. Kang, K. J. Savinainen, O. A. Janne, T. L. J. Tammela, R. L. Vessella, J. J. Palvimo and T. Visakorpi, “Expression of Androgen Receptor Coregulators in Prostate Cancer,” Clinical Cancer Research, Vol. 10, No. 3, 2004, pp. 1032-1040.
[69] J. G. Ma, W. P. Li and Y. Q. Jiang, “Androgen Receptor Mutation and Progression of Prostate Cancer,” Zhonghua Nan Ke Xue, Vol. 17, No. 7, 2011, pp. 649-654.
[70] S. Sluczanowska-Glabowska, M. Laszczynska, M. Wylot, W. Glabowski, M. Piasecka and D. Gacarzewicz, “Morphological and Immunohistological Compare of Three Rat Préstate Lobes (Lateral, Dorsal and Ventral) in Experimental Hyperprolactinemia,” Folia Histochemica et Cytobiologica, Vol. 48, No. 3, 2010, pp. 447-454.
[71] S. K. Hong, J. H. Kim, M. F. Lin and P. R. K. JI, “The Raf/MEK/Extracellular Signal-Regulated Kinase 1/2 Pathway Can Mediate Growth Inhibitory and Differentiation Signaling via Androgen Receptor Downregulation in Prostate Cancer Cells,” Experimental Cell Research, Vol. 317, No. 18, 2011, pp. 2671-2682.
[72] S. H. Tan, A. Dagvadorj, F. Shen, L. Gu, Z. Liao, J. Abdulghani, Y. Zhang, E. P. Gelmann, T. Zellweger, Z, Culig, T. Visakorpi, L. Bubendorf, R. A. Kirken, J. Karras and M. T. Nevalainen, “Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells,” Cancer Research, Vol. 68, No. 1, 2008, pp. 236-248.
[73] W. C. Guftason and W. A. Weiss, “Myc Proteins as Therapeutic Targets,” Oncogene, Vol. 29, No. 9, 2010, pp. 1249-1259.
[74] C. M. Koh, C. J. Bieberich, C. V. Dang, W. G. Nellson, S. Yegnasubramanian and A. M. DeMarzo, “Myc and Prostate Cancer,” Genes and Cancer, 2010, Vol. 1, No. 6, pp. 617-628.
[75] D. S. Rickman, T. D. Soonfg, B. Moss, J. M. Mosquera, J. Dlabal, S. Terry, T. Y. MacDonald, J. Tripodi, K. Bunting, V. Najfeld, F. Demichelis, A. M. Melnick, O. Elemento and M. A. Rubin, “Oncogene-Mediated Alterations in Chromatin Conformation,” Proceedings of the National Academy of Sciences, 2012, Vol. 109, No. 23, pp. 9083-9088.
[76] J. Wang, T. Kobayashi, N. Floch, C.W. Kinkade, A. Aytes, D. Dankort, C. Lefevbre, A. Mitrofanova, R. D. Car- diff, M. McMahon, A. Califano, M. M. Shen and C. Anatte-Shen, “B-Raf Activation Cooperates with PTEN Loss to Drive c-myc Expression in Advanced Prostate Cancer,” Cancer Research, 2012, Vol. 72, No. 18, pp. 1-12.
[77] M. D. Amatangelo, S. Goodyear, D. Varma and M. E. Stearns, “c-Myc Expression and MEK1-Induced Erk2 Nuclear Localization Are Required for TGF-Beta Induced Epithelial-Mesenchymal Transition and Invasion in Prostate Cancer,” Carcinogenesis, 2012, Vol. 1, No. 1, pp. 1965-1975.
[78] S. Yamamura, S. Saini, S, Majid, H. Hirata, K. Ueno, G. deng and R. Dahiya, “MicroRNA-34a Modulates c-myc Transcriptional Complex to Suppress Malignancy in Human Prostate Cancer Cells,” Plos ONE, Vol. 7, No. 1, pp. 1-12.
[79] B. Benassi, R. Flavin, L. Marchionni, S. Zanata, Y. Pan, D. Chowdhury, M. Marani, S. Strano, P. Muti, G. Blandino and M. Loda, “MYC Is Activated by USP2a-Mediated Modulation of microRNAs in Prostate Cancer,” Cancer Discovery, 2012, Vol. 2, No. 3, pp. 236-247.
[80] N. Nadiminty, R. Tummala, W. Lou, y. Zhu, J. Zhang, X. Chen, W. R. eVere-White, H. J. Kung, C. P. Evans and A. C. Gao, “MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells,” Jornal Biology Chemistry, 2012, Vol. 287, No. 2, pp. 1527-1537.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.